Researchers identify rituximab-insensitive cells in patients with refractory thrombocytopenia purpura

Posted By News On December 29, 2012 - 7:03pm

Primary immune thrombocytopenia purpura (ITP) is a bleeding disorder in which the immune system generates antibodies that destroy platelets, the cells that cause blood to clot. B cells, immune cells that produce the antibodies that recognize the platelets, develop in the spleen.

ITP patients are typically treated with rituximab, a drug that deplete B cells; however, many patients stop responding to this treatment and must have their spleens removed.

In the Journal of Clinical Investigation, researchers led by Jean-Claude Weill and Claude-Agnès Reynaud at the Université Paris Descartes in Paris identified antibody-producing cells in the spleens of ITP patients that were not sensitive to B-cell depleting drugs.

The development of these cells was promoted by rituximab treatment and provides an explanation for why some patients develop refractory ITP.

TITLE: B-cell depletion in immune thrombocytopenia reveals splenic long-lived plasma cells

Post new comment

The content of this field is kept private and will not be shown publicly.
  • Allowed HTML tags: <h> <a><em><img><strong><iframe><table><object><cite><p><br><i><b><center><ul><li><div><html5:figure><html5:figcaption><td><tr>
  • Lines and paragraphs break automatically.

More information about formatting options

Sorry, we know you're not a spambot, but they're out there